What to Do When Initial Guideline-Directed Medical Therapy Has Not Achieved Euvolemia in Heart Failure with Reduced Ejection Fraction
This protocol applies to patients with heart failure with reduced ejection fraction (HFrEF) who have been started on optimised guideline-directed medical therapy (GDMT) but have not yet eliminated clinical evidence of fluid retention and achieved stable euvolemia — the primary goal set for that first line of treatment.
Why escalation is triggered
First-line management initiates all four foundational drug classes of GDMT and, when congestion is present, adds a loop diuretic. If clinical evidence of fluid retention persists and euvolemia is not maintained, this protocol defines the next structured step.
Next-step approach (partial overview)
For patients already on optimised GDMT, the protocol selects additional targeted medical agents based on specific physiological criteria and symptom burden, and evaluates eligibility for device-based interventions. The full criteria, agent selection, and sequencing are contained in the complete structured protocol.
References
DOI: 10.1161/CIR.0000000000001063
- For patients with symptomatic (NYHA class II to III) stable chronic HFrEF (LVEF ≤35%) who are receiving GDMT, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of ≥70 bpm at rest, ivabradine can be beneficial to reduce HF hospitalizations and cardiovascular death.
- In patients with symptomatic HFrEF despite GDMT (or who are unable to tolerate GDMT), digoxin might be considered to decrease hospitalizations for HF.
- In selected high-risk patients with HFrEF and recent worsening of HF already on GDMT, an oral soluble guanylate cyclase stimulator (vericiguat) may be considered to reduce HF hospitalization and cardiovascular death.
- In patients with nonischemic DCM or ischemic heart disease at least 40 days post-MI with LVEF ≤35% and NYHA class II or III symptoms on chronic GDMT, who have reasonable expectation of meaningful survival for >1 year, ICD therapy is recommended for primary prevention of SCD to reduce total mortality.
- For patients who have LVEF ≤35%, sinus rhythm, left bundle branch block (LBBB) with a QRS duration ≥150 ms, and NYHA class II, III, or ambulatory IV symptoms on GDMT, CRT is indicated to reduce total mortality, reduce hospitalizations, and improve symptoms and QOL.
View source ↗